Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

China Pharma Holdings (CPHI) EPS (Weighted Average and Diluted) (2016 - 2025)

China Pharma Holdings (CPHI) has disclosed EPS (Weighted Average and Diluted) for 10 consecutive years, with -$0.17 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EPS (Weighted Average and Diluted) rose 73.85% year-over-year to -$0.17, compared with a TTM value of -$0.61 through Sep 2025, up 76.26%, and an annual FY2024 reading of -$0.27, up 70.33% over the prior year.
  • EPS (Weighted Average and Diluted) was -$0.17 for Q3 2025 at China Pharma Holdings, down from -$0.16 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at -$0.04 in Q4 2024 and bottomed at -$0.91 in Q2 2024.
  • Average EPS (Weighted Average and Diluted) over 3 years is -$0.4, with a median of -$0.26 recorded in 2023.
  • The sharpest move saw EPS (Weighted Average and Diluted) crashed 124.14% in 2024, then skyrocketed 82.42% in 2025.
  • Year by year, EPS (Weighted Average and Diluted) stood at -$0.29 in 2023, then soared by 86.21% to -$0.04 in 2024, then tumbled by 325.0% to -$0.17 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for CPHI at -$0.17 in Q3 2025, -$0.16 in Q2 2025, and -$0.24 in Q1 2025.